Vomaris Innovations, Inc., an electroceutical company specializing in microcurrent-generating solutions for the wound care market, has entered into an exclusive global commercial and development partnership for its microcurrent generating wound care products, Procellera antimicrobial wound dressings, with Arthrex, Inc.

Arthrex is a global medical device company and a leader in new product development and medical education in orthopaedics and sports medicine, operating in over 90 countries throughout the world.

"With the increasing market demand for non-pharmacologic solutions for infection prevention, improved post-operative outcomes and cost containment, the orthopaedic incision and wound care market has been a rapidly growing segment for us. We are extremely pleased to have Arthrex as our strategic orthopaedic distribution partner. With their strong reputation for innovation and unparalleled sales and marketing competencies, we are confident they will drive substantial penetration for Procellera," commented Michael Nagel, president and CEO of Vomaris Innovations, Inc.

Procellera antimicrobial wound dressing, the only wound dressing in the world powered by wireless advanced microcurrent technology, offers a new generation solution for wound and incisional care with demonstrated broad-spectrum antimicrobial and anti-biofilm efficacy, and the ability to accelerate cellular migration for enhanced wound healing. An active aging population demographic along with significant technological advancements have given rise to a dramatic increase in the number of total joint arthroplasties in the US.  The disturbing spread of multidrug-resistant bacteria following the widespread use of prolonged antimicrobial prophylaxis and substantial financial burden of periprosthetic joint infection (PJI) has highlighted the unmet need for non-systemic modalities that can both help prevent pathogenic contamination and expedite wound healing.  

"The Procellera product is the perfect finishing touch to our orthopaedic procedures. Shoulder and knee arthroscopy and arthroplasty, and foot and ankle procedures all have a risk of infection that can greatly inhibit a patient's return to normal activity. Expanding the use of products like Procellera with our existing procedures and products will have a positive impact on patient safety and health economics for our clients. This product aligns well with our goal to help our surgeons treat their patients better," said David Shepard, Orthobiologics Director of Arthrex.

Under the terms of this distribution agreement, Arthrex will have exclusive global distribution rights to Procellera Technology in the orthopaedic and sports medicine markets for both human and veterinary applications. Vomaris will have continued responsibility for manufacturing and ongoing research and development. Responsibilities related to future orthopaedic development programs utilizing Procellera Technology will be shared between both organizations.

Vomaris Innovations, Inc. is an electroceutical company specializing in microcurrent-generating solutions for the wound care market and beyond.